FDA Brief

Warning letters Biologics

FDA warning letter to

Central Coast Multispecialty Medical Group, Inc.

High riskIssued Jan 29Posted Feb 10Center for Biologics Evaluation and Research (CBER)

FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

What happened

FDA inspected the Monterey, CA firm from May 13, 2025, to May 16, 2025. It found the donor questionnaire did not screen for all communicable disease risks and that a directed semen donor who reported a risk factor was determined eligible. FDA also found donor eligibility was documented before test results for Chlamydia trachomatis, Neisseria gonorrhea, and HIV/HCV/HBV NAT were received.

What FDA found

  1. The donor eligibility questionnaire did not ask about all behaviors and conditions that raise the risk of communicable disease, such as certain sexual history, hepatitis, drug use, tattoos/piercings, smallpox vaccination, West Nile virus, and time spent in Europe.

    21 CFR 1271.75(a)(1)
  2. The firm determined a directed semen donor eligible even though the donor answered yes to having had sex with another man in the preceding five years, a risk factor.

    21 CFR 1271.75(d)
  3. The firm documented a donor as eligible before receiving results of required communicable disease tests, including Chlamydia trachomatis, Neisseria gonorrhea, and HIV/HCV/HBV NAT.

    21 CFR 1271.50(a); 21 CFR 1271.80; 21 CFR 1271.85
  4. The firm did not establish and maintain written procedures for all steps in testing, screening, and determining donor eligibility; it said policies were transmitted verbally and the policy book was only for compliance.

    21 CFR Part 1271, Subpart C

What FDA wants

FDA tells the firm to respond in writing within 15 working days with specific corrective steps, documentation of corrections, and how it will prevent recurrence. FDA also says affected HCT/Ps must stay in quarantine unless FDA grants an exemption or alternative.

Who should pay attention

  • fertility clinics that use donor eggs, sperm, or embryos
  • sperm and oocyte banks/donor tissue suppliers
  • laboratories and staff performing donor eligibility screening and testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  2. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  3. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk
  4. Lux Therapeutics LLC dba Ponya Therapeutics LLC

    FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.

    High risk